Login / Signup

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer.

Xinyi ZhouQian XiaoDongliang FuHaochen ZhangYang TangJinjie HeYeting HuXiangxing KongFei TengXiangrui LiuYing YuanKe-Feng Ding
Published in: Cancer biology & medicine (2021)
These data showed that targeting RAS signaling using RGS could be a therapeutic treatment for KRAS-mutant colorectal cancer patients.
Keyphrases
  • wild type
  • machine learning
  • cancer therapy
  • replacement therapy
  • smoking cessation